Abstract: The present application provides a battery including a shell, a top cover, a battery cell, and a second adapter part. The top cover seals an upper end of the shell and forms a cavity together with the shell, and the battery cell is located in the cavity. The shell includes a side wall surrounding the cavity and a bottom shell arranged at a lower end of the side wall. The battery cell has a first tab and a second tab, the bottom shell is electrically connected to the second tab, the second adapter part includes a second connection sheet and a second pin, the second adapter part is connected to the bottom shell through the second connection sheet; one end of the second pin is connected to the second connection sheet, and the other end thereof extends out of an outer edge of the bottom shell.

Abstract: An amphibious robot includes a housing including a first shell and a second shell and having a first configuration and a second configuration, a rack disposed in an inner cavity of the housing, a telescopic assembly disposed on the rack and connected between the first shell and the second shell, and a rotary wing assembly disposed on the rack and having a folded configuration and a flight configuration. The rotary wing assembly includes: a folding arm with one end rotatably connected to the rack, a rotary wing, and a tilting arm connected between the rotary wing and the folding arm, the tilting arm and the rotary wing are extended to an outside of the housing to be adapted to drive the robot to fly in the flight configuration, and the tilting arm is rotatable relative to the folding arm to adjust a rotation direction of the rotary wing.

Abstract: Disclosed is a battery, the battery including a housing, where the housing is a metal piece, the housing includes a bottom shell and a cap, and the cap covers an opening of the bottom shell; the cap includes a mounting hole, a conductive sealing pin disposed in the mounting hole, a side periphery of the sealing pin is provided with a clamping groove, and the cap close to the mounting hole extends into the clamping groove and is in clamped connection to the clamping groove; and a seal is provided at a connection between the clamping groove and the cap, and the seal is an electrical insulator. The structure improves application stability of the battery and improves sealing performance and safety of the battery.

Abstract: The present application provides a button cell and its manufacturing method and electronic equipment. The button cell includes a housing, an electrode assembly and a covering member, an accommodating cavity being provided in the housing, the electrode assembly being located in the accommodating cavity, the housing having a liquid injection hole for injecting electrolyte into the accommodating cavity; an outer surface of the housing having a recessed portion that is recessed towards an inner side of the accommodating cavity, the recessed portion being located at a orifice of the liquid injection hole and communicated with the liquid injection hole; and the covering member being welded to the outer side of the housing to cover the recessed portion and the liquid injection hole. The button cell and its manufacturing method and electronic equipment of the present.

Abstract: A battery case, a battery, and an electronic device include a case body, a first cover body, a first insulating part, and a second cover body, where the case body includes a bottom wall and a side wall connected to the bottom wall; the first cover body includes a first surface and a second surface disposed opposite to each other; the second cover body includes a third surface and a fourth surface disposed opposite to each other; the first surface of the first cover body is connected to one end of the side wall away from the bottom wall, and the second surface of the first cover body is connected to the third surface of the second cover body by the first insulating part.

Abstract: Disclosed herein are methods for diagnosing a subject as having a neurological disorder, such as Alzheimer's disease, using proximity-based detection assays capable of detecting complexes containing two or more synaptic proteins, such as neuronal pentraxins, from a blood, cerebrospinal fluid, or other fluid sample of the subject. Also disclosed are methods of evaluating and monitoring subjects having or at risk of developing a neurological disorder using the aforementioned assays.

Abstract: An electric pedal control device for an aircraft, the device comprising several pedal transmission assemblies, each of the pedal transmission assemblies comprising an electric motor, an elastic connector, a transmission mechanism, an angular displacement sensor, and a pedal, wherein the angular displacement sensor is configured to acquire rotational position information about the pedal; transmission mechanism revolute pairs of the transmission mechanisms in the pedal transmission assemblies are connected via a mechanical connecting rod mechanism to effect linkage; and a controller of the electric pedal control device is configured to receive the rotational position information, and to control, according to the rotational position information, the electric motors to dampen the elastic connectors.

Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control.

Abstract: An electric pedal control device for an aircraft, the device comprising several pedal transmission assemblies, each of the pedal transmission assemblies comprising an electric motor, an elastic connector, a transmission mechanism, an angular displacement sensor, and a pedal, wherein the angular displacement sensor is configured to acquire rotational position information about the pedal; transmission mechanism revolute pairs of the transmission mechanisms in the pedal transmission assemblies are connected via a mechanical connecting rod mechanism to effect linkage; and a controller of the electric pedal control device is configured to receive the rotational position information, and to control, according to the rotational position information, the electric motors to dampen the elastic connectors.

Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control.

Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control.

Abstract: The present invention relates to the field of cognitive function. More specifically, the present invention provides compositions and methods useful for assessing cognitive dysfunction/function in Alzheimer's disease and other diseases of cognition. In one embodiment, the method comprises the steps of (a) reducing heterocomplexes comprising NPTX1 and NPTX2 present in a biological sample obtained from the patient into NPTX1 and NPTX2 monomers; (b) covalently modifying the thiol groups of the NPTX1 and NPTX2 monomers to prevent re-formation of NPTX1/NPTX2 heterocomplexes; (c) detecting NPTX2 in the sample; and (d) assessing cognitive function in the patient by comparing NPTX2 detected in the sample to a control.

Abstract: Disclosed is an edible coating, a food product coated with the coating and the method for manufacturing the food product. The coating comprises a first layer comprising first edible oil and a second layer comprising a hydrophobic edible particle wherein the hydrophobic edible particle has a diameter from 20 nm to 500 microns. The food product having the coating is resistant to becoming soggy.

Abstract: The present invention is based on the discovery that neuronal pentraxins play a role in the clustering and internalization of AMPA receptors, synaptogenesis, and metabotropic glutamate receptor-mediated long term depression (LTD) of a synapse. Accordingly, there are provided methods of identifying compounds that that modulate mGluR-mediated AMPA receptor internalization and LTD. Further provided are cleavage products of a member of the neuronal pentraxin family, neuronal pentraxin receptor (NPR). Also provided are isolated peptides comprising the Narp association regions 1 and 2 (NAR1 and NAR2, respectively) and the Narp binding motif (NBM) of AMPA receptors. Finally, there are provided antibodies that block binding of neuronal pentraxins to AMPA receptors, in particular, antibodies that bind NAR1, or NAR2, or NBM.

Abstract: A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excretory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excretory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression.

Abstract: A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. The method also provides for a compound, for example, a long pentraxin polypeptide or fragment thereof, having a pentraxin binding domain and affecting AMPA receptor aggregation. The method provided herein affects AMPA receptor aggregation of GluR1, GluR2 and GluR3 receptor subunits.

Abstract: A method is provided for identifying a compound which affects the formation of AMPA receptors into aggregates. A method is also provided for identifying a compound which affects the formation of synaptic connections. A method is provided for identifying a compound that modulates immediate early gene expression. A method is further provided for increasing the number of excitory synapses of a neuron, including introducing into the neuron a polynucleotide sequence encoding a Narp operatively linked to a promoter, or a Narp polypeptide, thereby increasing the number of excitory synapses of the neuron. A method is provided for treating a subject with a disorder associated with a decrease in a function or expression of Narp, including administering to the subject a therapeutically effective amount of a compound that augments Narp function or expression.